JPS57181054A - Acetal-stabilized prostaglandin composition - Google Patents

Acetal-stabilized prostaglandin composition

Info

Publication number
JPS57181054A
JPS57181054A JP57063202A JP6320282A JPS57181054A JP S57181054 A JPS57181054 A JP S57181054A JP 57063202 A JP57063202 A JP 57063202A JP 6320282 A JP6320282 A JP 6320282A JP S57181054 A JPS57181054 A JP S57181054A
Authority
JP
Japan
Prior art keywords
acetal
prostaglandin composition
stabilized prostaglandin
stabilized
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57063202A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0219805B2 (OSRAM
Inventor
Daa Yu Chien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of JPS57181054A publication Critical patent/JPS57181054A/ja
Publication of JPH0219805B2 publication Critical patent/JPH0219805B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP57063202A 1981-04-16 1982-04-15 Acetal-stabilized prostaglandin composition Granted JPS57181054A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/254,824 US4358603A (en) 1981-04-16 1981-04-16 Acetal stabilized prostaglandin compositions

Publications (2)

Publication Number Publication Date
JPS57181054A true JPS57181054A (en) 1982-11-08
JPH0219805B2 JPH0219805B2 (OSRAM) 1990-05-07

Family

ID=22965721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57063202A Granted JPS57181054A (en) 1981-04-16 1982-04-15 Acetal-stabilized prostaglandin composition

Country Status (12)

Country Link
US (1) US4358603A (OSRAM)
EP (1) EP0063367B1 (OSRAM)
JP (1) JPS57181054A (OSRAM)
AT (1) ATE9061T1 (OSRAM)
AU (1) AU553104B2 (OSRAM)
CA (1) CA1168155A (OSRAM)
DE (1) DE3260600D1 (OSRAM)
HK (1) HK43987A (OSRAM)
IE (1) IE52854B1 (OSRAM)
MY (1) MY8700597A (OSRAM)
NZ (1) NZ200309A (OSRAM)
ZA (1) ZA822578B (OSRAM)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
TR200101905T2 (tr) 1997-04-28 2002-06-21 Texas Biotechnology Corporation Endotelin ile ilgili hastalıkların tedavisinde kullanılan sülfanoamidler.
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
US6696473B2 (en) * 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
WO2003059884A1 (en) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1521746B1 (en) 2002-03-07 2011-04-27 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
SI2177620T1 (sl) 2003-03-05 2015-02-27 Halozyme, Inc. Topen hialuronidazni glikoprotein (sHASEGP), postopek za pripravo le-tega, uporabe in farmacevtski sestavki, ki ga obsegajo
CA2525547C (en) * 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
ATE439837T1 (de) * 2003-06-03 2009-09-15 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
EP1911754B1 (en) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050203184A1 (en) 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
CA2583087C (en) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
JP2008505916A (ja) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド チロシンホスファターゼの酸素／窒素複素環阻害剤
JP2008505976A (ja) 2004-07-12 2008-02-28 アイディーユーエヌ・ファーマスーティカルズ・インコーポレーテッド テトラペプチド類似体
EP1841749A1 (en) 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ584773A (en) 2004-09-17 2012-07-27 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
NZ560354A (en) * 2005-06-17 2010-10-29 Ligand Pharm Inc Androgen receptor modulator compounds and methods
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
NZ570190A (en) 2006-01-24 2011-03-31 Sucampo Ag Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
CA2647543A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
TW201343676A (zh) 2006-08-28 2013-11-01 Kyowa Hakko Kirin Co Ltd 具拮抗性之人類ｌｉｇｈｔ專一性人類單株抗體
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2008054956A2 (en) 2006-10-09 2008-05-08 Takeda San Diego, Inc. Kinase inhibitors
US7943659B2 (en) 2006-10-31 2011-05-17 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
BRPI0817315A2 (pt) 2007-09-25 2015-03-17 Takeda Pharmaceutical Inibidores de quinase do tipo polo
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
CN105031628B (zh) 2009-01-06 2020-10-02 加尔纳根有限责任公司 治疗或预防大肠杆菌导致的经口感染的组合物和方法
EP2373791B1 (en) 2009-01-06 2016-03-30 Curelon LLC Compositions comprising protease, amylase and lipase for use in the treatment of staphylococcus aureus infections
WO2010111626A2 (en) 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011014681A1 (en) 2009-07-30 2011-02-03 Takeda Pharmaceutical Company Limited Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
US8871460B2 (en) 2009-11-09 2014-10-28 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
WO2011079313A1 (en) * 2009-12-23 2011-06-30 Map Pharmaceuticals, Inc. Novel ergoline analogs
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
EP2585455B1 (en) 2010-06-24 2019-08-07 The Regents of the University of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
ES2804223T3 (es) 2011-04-21 2021-02-04 Curemark Llc Compuestos para el tratamiento de Trastornos Neuropsiquiátricos
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
EP2793583A4 (en) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc NOVEL NEUROMODULATORY CONNECTIONS
US9567316B2 (en) 2012-03-07 2017-02-14 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US8551535B1 (en) 2012-08-06 2013-10-08 Sarah McCann Homeopathic remedies and methods for enhancing weight loss
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2934143A4 (en) 2012-12-21 2016-06-15 Map Pharmaceuticals Inc NOVEL DERIVATIVES OF METHYSERGIDE
HK1219654A1 (zh) 2013-02-22 2017-04-13 University Of Southern California 用於治疗眼科疾病和病症的方法
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
ES2834430T3 (es) 2013-03-15 2021-06-17 Univ Southern California Procedimientos, compuestos y composiciones para el tratamiento de enfermedades relacionadas con la angiotensina
CA2914369C (en) 2013-06-06 2023-02-14 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
CA2966423C (en) 2014-10-31 2023-10-24 The General Hospital Corporation Potent gamma-secretase modulators
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
US9676776B2 (en) 2015-01-20 2017-06-13 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
EP3265123B1 (en) 2015-03-03 2022-10-26 Kymab Limited Antibodies, uses & methods
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
WO2017096323A1 (en) 2015-12-02 2017-06-08 Astraea Therapeutics, Llc Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR20180119582A (ko) 2016-02-12 2018-11-02 파맥시스 엘티디 라이실 옥시다제의 인돌 및 아자인돌 할로알릴아민 유도체 억제제 및 이의 용도
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
US10407437B2 (en) 2016-03-08 2019-09-10 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
EP4190357A1 (en) 2016-05-13 2023-06-07 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
US10836774B2 (en) 2016-11-30 2020-11-17 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
US10513497B2 (en) 2017-02-17 2019-12-24 Eidos Therapeutics, Inc. Process for preparing AG-10, its intermediates, and salts thereof
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3630758A1 (en) 2017-06-01 2020-04-08 Xoc Pharmaceuticals, Inc Ergoline derivatives for use in medicine
EP3675866B1 (en) 2017-09-01 2023-08-02 East Carolina University Ex vivo methods for activating immune cells
WO2019099353A1 (en) 2017-11-15 2019-05-23 California State University Northridge Compositions and methods for the treatment and prevention of cancer
TW202425973A (zh) 2018-03-23 2024-07-01 美商文涵治療有限公司 使用ag10治療ttr澱粉樣沉積症之方法
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
JP7414803B2 (ja) 2018-08-03 2024-01-16 ファーマクシス リミテッド リシルオキシダーゼのハロアリルアミンスルホン誘導体阻害剤およびそれらの使用
SG11202101393PA (en) 2018-08-17 2021-03-30 Eidos Therapeutics Inc Formulations of ag10
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
US20220249707A1 (en) 2019-05-20 2022-08-11 Nirvana Sciences Inc. Narrow emission dyes, compositions comprising same, and methods for making and using same
AU2020348685A1 (en) 2019-09-16 2022-04-14 Dice Alpha, Inc. IL-17A modulators and uses thereof
JP2023532312A (ja) 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
BR112023018290A2 (pt) 2021-03-10 2023-12-12 Dice Molecules Sv Inc Inibidores da integrina alfa v beta 6 e alfa v beta 1 e usos dos mesmos
WO2023069770A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023168329A2 (en) 2022-03-02 2023-09-07 Mitopower, Inc. Novel prodrugs derived from nicotinic acid and ribose
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749800A (en) * 1971-11-01 1973-07-31 Upjohn Co Stable composition for dispensing pge2
US3833612A (en) * 1971-11-24 1974-09-03 Merck & Co Inc Derivatives of 5-oxo-1 beta-cyclopentane-heptanoic acid,5-ethylene acetals
US4178457A (en) * 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4178454A (en) * 1978-10-11 1979-12-11 Toray Industries, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
ZA822578B (en) 1983-11-30
EP0063367A1 (en) 1982-10-27
JPH0219805B2 (OSRAM) 1990-05-07
EP0063367B1 (en) 1984-08-22
CA1168155A (en) 1984-05-29
US4358603A (en) 1982-11-09
IE820889L (en) 1982-10-16
HK43987A (en) 1987-06-12
AU8263582A (en) 1982-10-21
IE52854B1 (en) 1988-03-30
DE3260600D1 (en) 1984-09-27
MY8700597A (en) 1987-12-31
AU553104B2 (en) 1986-07-03
ATE9061T1 (de) 1984-09-15
NZ200309A (en) 1985-03-20

Similar Documents

Publication Publication Date Title
JPS57181054A (en) Acetal-stabilized prostaglandin composition
IT7824093A0 (it) Analoghi prostaciclinici in cui l'atomo di ossigeno 6,9 alfa-epossi della prostaciclina e' sostituito da un atomo di azoto
JPS5477694A (en) Stable storable aqueous composition
AU559344B2 (en) Composition comprising sodium fluoride for dential cary control
AU553873B2 (en) Improving the filling capacity of tobacco
DE3170818D1 (en) Composition for reducing intraocular pressure
NO821570L (no) Fremstilling av en glutaraldehydforloeper.
ES8800598A1 (es) Un procedimiento para preparar una composicion farmaceutica que comprende azapropanona
IT1154279B (it) Procedimento per la produzione di soluzioni acquose di metioninato sodico a basso contenuto di carbonato sodico
BG32858A3 (bg) Метод за получаване на кристален натриев цефамандолметанолат
MY100078A (en) Improvements relating to the expansion of tobacco.
ES484321A1 (es) Un procedimiento para la preparacion de un compuesto de 3- carbamoiloximetil-cefalosporina
GB1382008A (en) Fungicidal and/or bacterial composition and method
AU509474B2 (en) Alcohol analogues of prostaglandins
IT1250638B (it) Procedimento per la preparazione di biciclo (3.2.0) ept-2-en-7-oni.
GB1532550A (en) Agent for preventing cold turbidity in beer
IT1169037B (it) Derivati della prostaciclina, loro preparazione e impiego
JPS5229185A (en) Semiconductor laser
GB2032419B (en) Hydantoin prostaglandin analogues
HUT48110A (en) Blood-analytic sampling and storing capillary tube and method for producing same
ES481140A1 (es) Procedimiento de obtencion de trimetilolpropano.
JPS532482A (en) Pyrimidine derivatives
SU1267745A1 (ru) Способ получения концентрированных водных растворов формальдегида
ES8505677A1 (es) Procedimiento para la preparacion del citrato de la (+) vinpocetina
JPS5382853A (en) Preparation of aqueous solutions of polyvinyl alcohol having low saponifica-tion degree